Study Type: POE Purpose: Which drug is better for agitation from dementia -quetiapine or rivastigmine? Does either drug cause cognitive decline? Study Duration: 26 weeks Patients: 93 patients, mean age 84 years, ~80% female; Baseline scales SIB = 62; CMAI = 59; FAST = 6 (see outcome measures) Trial Design: Double-blinded, placebo-controlled, randomized, all people with dementia in living care facilities in Newcastle Medications Target: quetiapine 25 -50 mg BID and Rivastigmine 3 -6 mg bid 3 groups -1) quetiapine + placebo rivastigmine; 2) placebo quetiapine + rivastigmine; 3) both placebo (double dummy) Inclusion Criteria: diagnosis of probable AD, age > 60, clinically significant agitation for at least 6 weeks, scores showing irritability and aberrant motor behavior Exclusion Criteria: those on antipsychotics or cholinesterase inhibitors for 4 weeks prior to study, severe disability, bradycardia, sick sinus syndrome, PUD Outcome Measures: Cohen-Mansfield agitation scale (CMAI); Severe Impairment Battery for agitation (SIB) -40 item test to evaluate cognitive dysfunction (memory, orientation, language, attention, praxis, social interaction, orientation to name); scores range from 0 to 100, higher scores reflect higher levels of cognition; FAST (Functional Assessment Staging) -assesses ability to perform daily life activities.
1.
Are the results valid? * randomized? Yes * double-blinded? Yes * placebo-controlled? Yes * were study groups similar? yes * all patients accounted for? Yes * allocation concealment? Yes
2.
What were the results? * no significant difference in change in agitation inventory scores (CMAI) between baseline and 26 weeks. * SIB -those patients on quetiapine had a significantly greater deterioration in cognitive functioning at 6 weeks (p = .009) and at 26 weeks (p = .01). There was no deterioration in the rivastigmine group as compared to placebo. * FAST data was not reported
3.
Will the results help me? * those with poor cognitive functioning were likely to drop out of the study * no adverse events reported Conclusion: Quetiapine does not result in significant improvement in agitation in patients with dementia and is associated with a greater decline in cognitive functioning. Patients in the rivastigmine group did not experience any improvement in agitation nor did they seem to experience a decline in cognition as compared to placebo.
